Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), […]